Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31167626 | 1.00 | LCK (0.51) | LCKNLRP3SYKATRPDK1 | |
| SCHEMBL1610508 | 0.90 | NLRP3 (0.53) | LCKNLRP3SYKATR | |
| SCHEMBL24574915 | 0.89 | LCK (0.60) | LCKNLRP3ATRTSHRHSD17B10 | |
| SCHEMBL19781758 | 0.83 | NLRP3 (0.53) | NLRP3TSHR | |
| SCHEMBL660566 | 0.83 | NLRP3 (0.43) | LCKNLRP3SYKATR | |
| SCHEMBL29741502 | 0.83 | HDAC1 (0.51) | LCKNLRP3SYKATR | |
| SCHEMBL23054108 | 0.83 | HTT (0.45) | LCKNLRP3SYKATR | |
| SCHEMBL2997409 | 0.83 | LCK (0.52) | LCKNLRP3ATRTSHRHSD17B10 | |
| SCHEMBL4922310 | 0.82 | LMNA (0.43) | LCKNLRP3SYKATRPDK1 | |
| SCHEMBL1346055 | 0.82 | ALB (0.44) | LCKNLRP3SYKATRPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603878-B1 | PROCESSES FOR THE PREPARATION OF N-HETEROARYL-N-ARYL-AMINES BY REACTING AN N-ARYL CARBAMIC ACID ESTER WITH A HALO-HETEROARYL AND ANALOGOUS PROCESSES | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1418900-A4 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1339683-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040210080-A1 | Selective estrogen receptor modulators | MERCK & CO., INC. | 2004-10-21 | — | — | US | disclosed |
| EP-1418900-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1339683-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003015761-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002041835-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210080-A1 | Selective estrogen receptor modulators | GPER1, ESR2, ESR1 | LCK 2654/4885NLRP3 2966/4885SYK 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.